GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Price-to-Owner-Earnings

Biofrontera (Biofrontera) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Price-to-Owner-Earnings?

As of today (2024-05-17), Biofrontera's share price is $1.07. Biofrontera does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Biofrontera's Price-to-Owner-Earnings or its related term are showing as below:


BFRI's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.16
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-17), Biofrontera's share price is $1.07. Biofrontera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.92. Therefore, Biofrontera's PE Ratio for today is At Loss.

As of today (2024-05-17), Biofrontera's share price is $1.07. Biofrontera's EPS without NRI for the trailing twelve months (TTM) ended in was $-12.96. Therefore, Biofrontera's PE Ratio without NRI for today is At Loss.

During the past 5 years, Biofrontera's highest PE Ratio without NRI was 16.46. The lowest was 0.00. And the median was 13.47.


Biofrontera Price-to-Owner-Earnings Historical Data

The historical data trend for Biofrontera's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Price-to-Owner-Earnings Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Biofrontera Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biofrontera's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Biofrontera's Price-to-Owner-Earnings falls into.



Biofrontera Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biofrontera's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.07/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofrontera  (NAS:BFRI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Biofrontera Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Biofrontera's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera (Biofrontera) Business Description

Traded in Other Exchanges
N/A
Address
120 Presidential Way, Suite 330, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Executives
Heikki Lanckriet director C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler officer: Chief Financial Officer 84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber director 119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii director 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman director 5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge director 21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera 10 percent owner HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates officer: Controller C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco director, officer: Chief Financial Officer/COO C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert director, officer: Chief Executive Officer C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801